$11.8 Billion is the total value of Baker Brothers Advisors's 114 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 18.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $2,852,448,000 | -12.0% | 34,230,751 | +0.0% | 24.18% | -14.0% |
| SGEN | Buy | Seattle Genetics, Inc. | $2,594,777,000 | +6.1% | 49,575,409 | +8.4% | 21.99% | +3.7% |
| BGNE | Buy | BeiGene, Ltd.sponsored adr | $979,344,000 | +160.4% | 5,829,429 | +51.4% | 8.30% | +154.6% |
| ALXN | Buy | Alexion Pharmaceuticals, Inc. | $953,640,000 | -6.8% | 8,555,894 | +0.0% | 8.08% | -8.8% |
| BMRN | BioMarin Pharmaceutical Inc. | $614,761,000 | -9.1% | 7,583,084 | 0.0% | 5.21% | -11.1% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $611,821,000 | -25.4% | 27,228,338 | 0.0% | 5.19% | -27.0% | |
| GHDX | Buy | Genomic Health, Inc. | $431,487,000 | -8.5% | 13,789,936 | +0.1% | 3.66% | -10.5% |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $185,563,000 | +76.9% | 2,837,352 | +8.3% | 1.57% | +73.0% |
| AQXP | Aquinox Pharmaceuticals, Inc. | $153,953,000 | +19.7% | 10,934,154 | 0.0% | 1.30% | +17.0% | |
| AVXS | Buy | AveXis, Inc. | $144,237,000 | +68.2% | 1,167,157 | +50.6% | 1.22% | +64.6% |
| HRTX | Buy | Heron Therapeutics, Inc. | $138,698,000 | +150.4% | 5,025,298 | +64.2% | 1.18% | +145.0% |
| DBVT | DBV Technologies S.A.sponsored adr | $127,106,000 | -6.2% | 5,509,560 | 0.0% | 1.08% | -8.3% | |
| ABLX | Sell | Ablynx NVsponsored adr | $118,766,000 | +14.2% | 2,176,802 | -47.7% | 1.01% | +11.8% |
| SAGE | Buy | Sage Therapeutics, Inc. | $104,185,000 | +2.6% | 646,828 | +4.9% | 0.88% | +0.3% |
| ARRY | Array BioPharma Inc. | $92,309,000 | +27.5% | 5,656,196 | 0.0% | 0.78% | +24.5% | |
| ONCE | Spark Therapeutics, Inc. | $92,169,000 | +29.5% | 1,384,130 | 0.0% | 0.78% | +26.6% | |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $78,338,000 | +0.5% | 944,624 | -6.0% | 0.66% | -1.8% |
| MRTX | Mirati Therapeutics, Inc. | $78,268,000 | +68.2% | 2,549,461 | 0.0% | 0.66% | +64.5% | |
| ARGX | argenx SEsponsored adr | $77,363,000 | +27.4% | 961,754 | 0.0% | 0.66% | +24.7% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $71,906,000 | +27.2% | 615,684 | 0.0% | 0.61% | +24.3% | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $71,100,000 | +84.0% | 38,641,462 | +111.0% | 0.60% | +80.0% |
| AMRN | Amarin Corporation plcsponsored adr new | $68,235,000 | -24.9% | 22,669,509 | 0.0% | 0.58% | -26.6% | |
| BCRX | Buy | BioCryst Pharmaceuticals, Inc. | $66,838,000 | -2.7% | 14,012,172 | +0.1% | 0.57% | -4.9% |
| ERYP | ERYTECH Pharma S.A.sponsored adr | $64,891,000 | -4.6% | 3,090,069 | 0.0% | 0.55% | -6.8% | |
| Novavax, Inc.note 3.75% 2/1/2023 | $61,864,000 | +51.4% | 88,500,000 | 0.0% | 0.52% | +48.0% | ||
| CERS | Buy | Cerus Corporation | $58,910,000 | +78.8% | 10,749,937 | +10.3% | 0.50% | +74.5% |
| CBAY | Buy | CymaBay Therapeutics, Inc. | $50,891,000 | +84.9% | 3,917,700 | +30.9% | 0.43% | +80.3% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $40,775,000 | -31.5% | 2,049,020 | 0.0% | 0.35% | -32.9% | |
| NVTA | Buy | Invitae Corporation | $39,393,000 | -40.5% | 8,399,411 | +15.2% | 0.33% | -41.8% |
| BLUE | bluebird bio, Inc. | $34,150,000 | -4.1% | 200,000 | 0.0% | 0.29% | -6.5% | |
| ABEO | Buy | Abeona Therapeutics Inc. | $31,346,000 | -0.3% | 2,184,364 | +10.1% | 0.27% | -2.6% |
| HALO | Halozyme Therapeutics, Inc. | $30,980,000 | -3.3% | 1,581,424 | 0.0% | 0.26% | -5.4% | |
| SGMO | Sell | Sangamo Therapeutics, Inc. | $30,544,000 | -11.9% | 1,607,579 | -23.9% | 0.26% | -13.7% |
| NKTR | Buy | Nektar Therapeutics | $29,264,000 | +185.0% | 275,396 | +60.2% | 0.25% | +178.7% |
| BLCM | Sell | Bellicum Pharmaceuticals, Inc. | $27,234,000 | -35.7% | 4,151,578 | -17.5% | 0.23% | -37.1% |
| MNLO | New | Menlo Therapeutics Inc. | $26,306,000 | – | 700,000 | +100.0% | 0.22% | – |
| XNCR | Xencor, Inc. | $26,145,000 | +36.8% | 872,072 | 0.0% | 0.22% | +33.7% | |
| GLPG | Galapagos NVsponsored adr | $25,927,000 | +6.4% | 259,894 | 0.0% | 0.22% | +4.3% | |
| EXEL | Sell | Exelixis, Inc. | $25,753,000 | -43.8% | 1,162,644 | -22.8% | 0.22% | -45.1% |
| GWPH | GW Pharmaceuticals plcads | $24,990,000 | -14.7% | 221,800 | 0.0% | 0.21% | -16.5% | |
| MRUS | Merus N.V. | $21,495,000 | -4.5% | 1,160,014 | 0.0% | 0.18% | -6.7% | |
| AIMT | Aimmune Therapeutics, Inc. | $21,450,000 | -15.8% | 673,908 | 0.0% | 0.18% | -17.6% | |
| ECYT | Buy | Endocyte, Inc. | $20,705,000 | +344.9% | 2,277,799 | +109.5% | 0.18% | +337.5% |
| NTLA | Sell | Intellia Therapeutics, Inc. | $17,585,000 | -20.1% | 833,795 | -27.2% | 0.15% | -22.0% |
| PGNX | Sell | Progenics Pharmaceuticals, Inc. | $17,204,000 | -8.2% | 2,306,184 | -26.8% | 0.15% | -9.9% |
| INSM | Insmed Incorporated | $15,764,000 | -27.8% | 700,000 | 0.0% | 0.13% | -29.1% | |
| BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $14,099,000 | -5.6% | 15,000,000 | 0.0% | 0.12% | -7.0% | ||
| MYOK | Sell | MyoKardia, Inc. | $14,165,000 | -5.3% | 290,264 | -18.3% | 0.12% | -7.7% |
| BioMarin Pharmaceutical Inc.note 0.75% 10/15/2018 | $12,537,000 | -5.2% | 12,228,000 | 0.0% | 0.11% | -7.8% | ||
| BOLD | New | Audentes Therapeutics, Inc. | $11,816,000 | – | 393,222 | +100.0% | 0.10% | – |
| QURE | Buy | uniQure N.V. | $11,750,000 | +24.3% | 500,000 | +3.6% | 0.10% | +22.0% |
| CFRX | ContraFect Corporation | $11,625,000 | +60.9% | 7,153,076 | 0.0% | 0.10% | +57.1% | |
| AERI | Sell | Aerie Pharmaceuticals, Inc. | $11,699,000 | -34.6% | 215,655 | -28.0% | 0.10% | -36.1% |
| AGLE | Aeglea BioTherapeutics, Inc. | $11,288,000 | +83.4% | 1,137,872 | 0.0% | 0.10% | +81.1% | |
| New | Corsicanto II Designated Activity Companynote 3.5% 1/5/2047 | $11,025,000 | – | 10,000,000 | +100.0% | 0.09% | – | |
| ACHN | Achillion Pharmaceuticals, Inc. | $10,598,000 | +28.8% | 2,856,637 | 0.0% | 0.09% | +26.8% | |
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $10,471,000 | -54.2% | 4,381,072 | -25.1% | 0.09% | -55.1% |
| VNDA | Buy | Vanda Pharmaceuticals Inc. | $10,116,000 | +57.0% | 600,354 | +41.6% | 0.09% | +53.6% |
| ASMB | Sell | Assembly Biosciences, Inc. | $9,523,000 | -34.8% | 193,787 | -40.0% | 0.08% | -36.2% |
| ANAB | Sell | AnaptysBio, Inc. | $9,480,000 | -48.1% | 91,086 | -49.8% | 0.08% | -49.4% |
| MGNX | MacroGenics, Inc. | $9,150,000 | +32.4% | 363,676 | 0.0% | 0.08% | +30.0% | |
| GLYC | GlycoMimetics, Inc. | $9,143,000 | -3.3% | 563,312 | 0.0% | 0.08% | -6.1% | |
| RIGL | Rigel Pharmaceuticals, Inc. | $8,917,000 | -8.8% | 2,518,882 | 0.0% | 0.08% | -10.6% | |
| FOMX | Sell | Foamix Pharmaceuticals Ltd. | $8,203,000 | -44.7% | 1,598,991 | -35.2% | 0.07% | -45.3% |
| ALBO | Buy | Albireo Pharma, Inc. | $8,143,000 | +59.0% | 250,000 | +25.0% | 0.07% | +56.8% |
| GNMX | Aevi Genomic Medicine, Inc. | $8,151,000 | +67.5% | 4,055,142 | 0.0% | 0.07% | +64.3% | |
| SYRS | Syros Pharmaceuticals, Inc. | $7,461,000 | +33.4% | 574,835 | 0.0% | 0.06% | +31.2% | |
| Aegerion Pharmaceuticals, Inc.note 2.0% 8/15/2019 | $7,273,000 | -3.9% | 9,517,000 | 0.0% | 0.06% | -6.1% | ||
| XLRN | Acceleron Pharma Inc. | $6,408,000 | -7.9% | 163,900 | 0.0% | 0.05% | -10.0% | |
| GTHX | New | G1 Therapeutics, Inc. | $6,280,000 | – | 169,492 | +100.0% | 0.05% | – |
| ALKS | Sell | Alkermes plc | $5,811,000 | -29.3% | 100,251 | -33.3% | 0.05% | -31.0% |
| SBPH | Spring Bank Pharmaceuticals, Inc. | $5,739,000 | +14.4% | 373,144 | 0.0% | 0.05% | +14.0% | |
| IFRX | InflaRx N.V. | $5,768,000 | +37.7% | 200,000 | 0.0% | 0.05% | +36.1% | |
| CCXI | Buy | ChemoCentryx, Inc. | $5,631,000 | +1828.4% | 414,029 | +743.9% | 0.05% | +1500.0% |
| MNTA | New | Momenta Pharmaceuticals, Inc. | $5,599,000 | – | 308,500 | +100.0% | 0.05% | – |
| Inotek Pharmaceuticals Corp.note 5.75% 8/1/2021 | $4,795,000 | +19.6% | 5,000,000 | 0.0% | 0.04% | +17.1% | ||
| Nabriva Therapeutics plc | $4,719,000 | -15.9% | 938,235 | 0.0% | 0.04% | -18.4% | ||
| LJPC | La Jolla Pharmaceutical Company | $4,606,000 | -7.5% | 154,675 | 0.0% | 0.04% | -9.3% | |
| SLDB | New | Solid Biosciences Inc. | $4,409,000 | – | 587,884 | +100.0% | 0.04% | – |
| STML | Sell | Stemline Therapeutics, Inc. | $4,404,000 | -55.4% | 287,827 | -54.6% | 0.04% | -57.0% |
| NVAX | Novavax, Inc. | $4,200,000 | +69.4% | 2,000,000 | 0.0% | 0.04% | +71.4% | |
| ADMS | Adamas Pharmaceuticals, Inc. | $4,126,000 | -29.5% | 172,630 | 0.0% | 0.04% | -31.4% | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $4,030,000 | -14.1% | 660,714 | 0.0% | 0.03% | -17.1% | |
| CMTA | Clementia Pharmaceuticals Inc. | $3,788,000 | -20.2% | 250,000 | 0.0% | 0.03% | -22.0% | |
| NLNK | Sell | NewLink Genetics Corporation | $3,678,000 | -55.0% | 507,273 | -49.6% | 0.03% | -56.3% |
| Trillium Therapeutics Inc. | $2,947,000 | -0.7% | 409,323 | 0.0% | 0.02% | -3.8% | ||
| TTPH | Tetraphase Pharmaceuticals, Inc. | $2,870,000 | -51.3% | 935,000 | 0.0% | 0.02% | -52.9% | |
| VSAR | Versartis, Inc. | $2,353,000 | -25.0% | 1,426,310 | 0.0% | 0.02% | -25.9% | |
| JNCE | Jounce Therapeutics, Inc. | $2,235,000 | +75.3% | 100,000 | 0.0% | 0.02% | +72.7% | |
| TNXP | Tonix Pharmaceuticals Holdings Corp. | $2,098,000 | -13.1% | 699,500 | 0.0% | 0.02% | -14.3% | |
| NTRA | Natera, Inc. | $2,120,000 | +3.1% | 228,676 | 0.0% | 0.02% | 0.0% | |
| KRYS | Krystal Biotech, Inc. | $2,018,000 | -4.1% | 200,000 | 0.0% | 0.02% | -5.6% | |
| OVID | Sell | Ovid Therapeutics Inc. | $1,751,000 | -46.8% | 247,733 | -25.7% | 0.02% | -48.3% |
| TRVN | Trevena, Inc. | $1,558,000 | +2.5% | 950,000 | 0.0% | 0.01% | 0.0% | |
| CLLS | Cellectis S.A.sponsored ads | $1,576,000 | +8.1% | 50,000 | 0.0% | 0.01% | 0.0% | |
| DVAX | Dynavax Technologies Corporation | $1,489,000 | +6.1% | 75,000 | 0.0% | 0.01% | +8.3% | |
| SNSS | Sell | Sunesis Pharmaceuticals, Inc. | $1,514,000 | -44.7% | 556,665 | -24.9% | 0.01% | -45.8% |
| MDWD | MediWound Ltd. | $1,175,000 | +16.8% | 226,000 | 0.0% | 0.01% | +11.1% | |
| INFI | Infinity Pharmaceuticals, Inc. | $1,219,000 | +3.5% | 580,400 | 0.0% | 0.01% | 0.0% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $1,123,000 | +68.1% | 100,000 | 0.0% | 0.01% | +66.7% | |
| RARX | Ra Pharmaceuticals, Inc. | $945,000 | -37.5% | 177,952 | 0.0% | 0.01% | -38.5% | |
| SELB | Sell | Selecta Biosciences, Inc. | $955,000 | -65.7% | 93,750 | -67.0% | 0.01% | -66.7% |
| ABUS | Arbutus Biopharma Corporation | $903,000 | -1.0% | 180,582 | 0.0% | 0.01% | 0.0% | |
| AFMD | Affimed N.V. | $740,000 | +42.3% | 400,000 | 0.0% | 0.01% | +20.0% | |
| RTTR | New | Ritter Pharmaceuticals, Inc. | $762,000 | – | 279,999 | +100.0% | 0.01% | – |
| TTOO | T2 Biosystems, Inc. | $649,000 | +57.5% | 100,000 | 0.0% | 0.01% | +50.0% | |
| PRTO | Proteon Therapeutics, Inc. | $746,000 | +31.6% | 298,591 | 0.0% | 0.01% | +20.0% | |
| MTEM | Molecular Templates, Inc. | $579,000 | -20.2% | 72,412 | 0.0% | 0.01% | -16.7% | |
| AKTX | Sell | Akari Therapeutics, Plcsponsored adr | $618,000 | -79.5% | 339,833 | -51.2% | 0.01% | -80.8% |
| BDSI | BioDelivery Sciences International, Inc. | $473,000 | -23.7% | 210,021 | 0.0% | 0.00% | -20.0% | |
| FLGT | Fulgent Genetics, Inc. | $500,000 | -8.8% | 125,000 | 0.0% | 0.00% | -20.0% | |
| IMDZ | Immune Design Corp. | $491,000 | -15.5% | 148,937 | 0.0% | 0.00% | -20.0% | |
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $77,000 | -16.3% | 13,253 | 0.0% | 0.00% | 0.0% | |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $2,000 | 0.0% | 20,084 | 0.0% | 0.00% | – | |
| TENX | Exit | Tenax Therapeutics, Inc. | $0 | – | -348,374 | -100.0% | -0.00% | – |
| NVIV | Exit | InVivo Therapeutics Holdings Corp. | $0 | – | -331,393 | -100.0% | -0.00% | – |
| FPRX | Exit | Five Prime Therapeutics, Inc. | $0 | – | -19,247 | -100.0% | -0.00% | – |
| RTTR | Exit | Ritter Pharmaceuticals, Inc. | $0 | – | -2,800,000 | -100.0% | -0.01% | – |
| AKAOQ | Exit | Achaogen, Inc. | $0 | – | -122,482 | -100.0% | -0.01% | – |
| KPTI | Exit | Karyopharm Therapeutics Inc. | $0 | – | -216,990 | -100.0% | -0.02% | – |
| Exit | Protalix BioTherapeutics, Inc.note 4.5% 9/15/2018 | $0 | – | -3,423,000 | -100.0% | -0.02% | – | |
| EPZM | Exit | Epizyme, Inc. | $0 | – | -232,481 | -100.0% | -0.02% | – |
| ACOR | Exit | Acorda Therapeutics, Inc. | $0 | – | -205,966 | -100.0% | -0.04% | – |
| AAAP | Exit | Advanced Accelerator Applications S.A.sponsored ads | $0 | – | -55,125 | -100.0% | -0.04% | – |
| AGIO | Exit | Agios Pharmaceuticals, Inc. | $0 | – | -128,666 | -100.0% | -0.06% | – |
| ITCI | Exit | Intra-Cellular Therapies, Inc. | $0 | – | -609,166 | -100.0% | -0.08% | – |
| LGND | Exit | Ligand Pharmaceuticals Incorporated | $0 | – | -73,386 | -100.0% | -0.09% | – |
| IMGN | Exit | ImmunoGen, Inc. | $0 | – | -2,563,489 | -100.0% | -0.14% | – |
| Exit | Acorda Therapeutics, Inc.note 1.75% 6/15/2021 | $0 | – | -35,083,000 | -100.0% | -0.26% | – | |
| RXDX | Exit | Ignyta, Inc. | $0 | – | -1,384,266 | -100.0% | -0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.